CRH Medical Corp.

CRH-T

Analysis and Opinions about CRH-T

Signal
Opinion
Expert
WATCH
WATCH
January 17, 2020
He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has picked up so he will be watching it.
Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
January 17, 2020
He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has picked up so he will be watching it.
WEAK BUY
WEAK BUY
January 16, 2020
Perhaps sideways period is ending. Breakout, look for volume to support it. Keep in mind that $5 stocks are not being eaten up by institutional investors. As long as retail likes it, it will go up. Looks OK from his technical perspective.
Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
January 16, 2020
Perhaps sideways period is ending. Breakout, look for volume to support it. Keep in mind that $5 stocks are not being eaten up by institutional investors. As long as retail likes it, it will go up. Looks OK from his technical perspective.
COMMENT
COMMENT
March 11, 2019
It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
Show full opinionHide full opinion
It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
PARTIAL BUY
PARTIAL BUY
January 28, 2019
A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
January 28, 2019
A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
TOP PICK
TOP PICK
November 30, 2018
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
November 30, 2018
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
BUY
BUY
April 5, 2018

He was long about a year ago. It had a rough ride but he is long again now. The valuation has become compelling. Good balance sheet and debt not a problem.

Show full opinionHide full opinion

He was long about a year ago. It had a rough ride but he is long again now. The valuation has become compelling. Good balance sheet and debt not a problem.

COMMENT
COMMENT
January 24, 2018

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
January 24, 2018

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

COMMENT
COMMENT
December 15, 2017

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
December 15, 2017

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

WATCH
WATCH
December 4, 2017

He was one of the first buyers. He sold half his position when it was disproportionately high and then the rest on the way down. The market has lost confidence in management, who also sold a lot of shares in the $7 range. If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
December 4, 2017

He was one of the first buyers. He sold half his position when it was disproportionately high and then the rest on the way down. The market has lost confidence in management, who also sold a lot of shares in the $7 range. If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

COMMENT
COMMENT
November 24, 2017

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
November 24, 2017

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

DON'T BUY
DON'T BUY
November 14, 2017

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
November 14, 2017

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

COMMENT
COMMENT
November 13, 2017

They are in the US mainly and partner with anesthesiologists, for gut surgeries. There is a whole system in the US as to who can treat whom and what they will pay. These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward. He thinks it is overdone.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
November 13, 2017

They are in the US mainly and partner with anesthesiologists, for gut surgeries. There is a whole system in the US as to who can treat whom and what they will pay. These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward. He thinks it is overdone.

PAST TOP PICK
PAST TOP PICK
November 8, 2017

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
November 8, 2017

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

DON'T BUY
DON'T BUY
October 19, 2017

It has not done anything at all for him and is on a short leash. It is drifting back now. He would be concerned about tax loss selling soon. There is value there but don’t start a position.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
October 19, 2017

It has not done anything at all for him and is on a short leash. It is drifting back now. He would be concerned about tax loss selling soon. There is value there but don’t start a position.

TOP PICK
TOP PICK
October 4, 2017

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

Show full opinionHide full opinion

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

SELL
SELL
September 28, 2017

He exited this story. He was a big bull. It came back for stock specific stories. Multiple compression resulted from short reports.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
September 28, 2017

He exited this story. He was a big bull. It came back for stock specific stories. Multiple compression resulted from short reports.

HOLD
HOLD
September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

Show full opinionHide full opinion
CRH Medical Corp. (CRH-T)
September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

DON'T BUY
DON'T BUY
August 23, 2017

It had an amazing run this year. It was a target of some short sellers, and then they missed on some earnings reports. It is the worst for price momentum. It is actually okay on valuation. It has a decent balance sheet. It is volatile and has poor price momentum.

Show full opinionHide full opinion

It had an amazing run this year. It was a target of some short sellers, and then they missed on some earnings reports. It is the worst for price momentum. It is actually okay on valuation. It has a decent balance sheet. It is volatile and has poor price momentum.

WEAK BUY
WEAK BUY
August 22, 2017

It fell apart and is now working itself back. It got destroyed by credibility, short sellers came along and the stock has readjusted. He thinks the worst is over. It has earnings potential.

Show full opinionHide full opinion

It fell apart and is now working itself back. It got destroyed by credibility, short sellers came along and the stock has readjusted. He thinks the worst is over. It has earnings potential.

COMMENT
COMMENT
August 15, 2017

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

Show full opinionHide full opinion

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

COMMENT
COMMENT
August 2, 2017

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

Show full opinionHide full opinion

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

COMMENT
COMMENT
July 26, 2017

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

Show full opinionHide full opinion

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

COMMENT
COMMENT
July 24, 2017

News items make it difficult for anyone to analyze. They have one of the best returns of capital. The rules have changed. Probably it is okay. Usually the rule changes sound more threatening than they really are.

Show full opinionHide full opinion

News items make it difficult for anyone to analyze. They have one of the best returns of capital. The rules have changed. Probably it is okay. Usually the rule changes sound more threatening than they really are.

WATCH
WATCH
July 17, 2017

He has no price target. It is another great Canadian healthcare stock that got hammered a short while ago. The reason for the most recent decline is that Central Medical Services has changed how they code some services. This company should eventually be at higher prices, but he wants to see the dust settle.

Show full opinionHide full opinion

He has no price target. It is another great Canadian healthcare stock that got hammered a short while ago. The reason for the most recent decline is that Central Medical Services has changed how they code some services. This company should eventually be at higher prices, but he wants to see the dust settle.

HOLD
HOLD
July 13, 2017

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on. He thinks the short thesis is a little overplayed.

Show full opinionHide full opinion

An outsourcer in medical clinics where they take a 50% stake in the business. Registered nurses are being paid as full medical doctors. Their profitability could be hit when they are re-rated. The argument goes on. He thinks the short thesis is a little overplayed.

COMMENT
COMMENT
July 10, 2017

When a Short report came out, this dropped about 30%. Had sold about half his position in the $11 range to take some risk off the table. The stock is now close to the level, where if it breaches it, he will be selling his position. Believes their business is strong. He likes the company, but is just a little worried about it technically right now. On a P/E ratio, they seem really expensive. They have a nice ROE.

Show full opinionHide full opinion

When a Short report came out, this dropped about 30%. Had sold about half his position in the $11 range to take some risk off the table. The stock is now close to the level, where if it breaches it, he will be selling his position. Believes their business is strong. He likes the company, but is just a little worried about it technically right now. On a P/E ratio, they seem really expensive. They have a nice ROE.

WATCH
WATCH
June 30, 2017

Going ahead 3 or 4 years, he is pretty comfortable that the whole medical space will be higher. We are in a secular bull market with healthcare. It had a big spike down this year, but the range we are in now has provided some support. There was a low of $6.84 in May, but doesn’t think it is going back there. It seems to be basing around $7.23-$7.38. Look for this to break out at around $7.65-$7.73, which will tell him it is really getting some legs. It is probably going to base here for a while.

Show full opinionHide full opinion

Going ahead 3 or 4 years, he is pretty comfortable that the whole medical space will be higher. We are in a secular bull market with healthcare. It had a big spike down this year, but the range we are in now has provided some support. There was a low of $6.84 in May, but doesn’t think it is going back there. It seems to be basing around $7.23-$7.38. Look for this to break out at around $7.65-$7.73, which will tell him it is really getting some legs. It is probably going to base here for a while.

PAST TOP PICK
PAST TOP PICK
June 22, 2017

(Top Pick Jun 30/16, Up 52%) It was almost $12 at one point and was really stretched, then a short report came out, all before he bought it. He likes the business and feels they will continue to do well. They have great cash flow for acquisitions.

Show full opinionHide full opinion

(Top Pick Jun 30/16, Up 52%) It was almost $12 at one point and was really stretched, then a short report came out, all before he bought it. He likes the business and feels they will continue to do well. They have great cash flow for acquisitions.

COMMENT
COMMENT
May 25, 2017

This got up to $11-$12, where he thought it was a little ahead of itself. Markets were jittery and someone came out with a Short report, so a lot of Shorts piled on and the stock came off quite a bit. At the current value of around $8, it looks half decent. He is comfortable with management.

Show full opinionHide full opinion

This got up to $11-$12, where he thought it was a little ahead of itself. Markets were jittery and someone came out with a Short report, so a lot of Shorts piled on and the stock came off quite a bit. At the current value of around $8, it looks half decent. He is comfortable with management.

COMMENT
COMMENT
May 5, 2017

A recent Short report made some interesting points. Although he doesn’t like serial acquisitors, he likes that this company is very focused on what they are doing. When they make an acquisition, they typically get 50%-51% of the business, so they consolidate it. Their revenue numbers are generally growing much faster than their earnings because they have to take out the minority interests. They are recognizing 100% of the revenues, but effectively are only getting 51% of the earnings. That was one of the thrusts of the Short report. The other was that they were being paid to use an MD to administer their deep sedation (used in colonoscopies), but using specially trained professional nurses instead. A decent company, he is just not sold on it yet.

Show full opinionHide full opinion

A recent Short report made some interesting points. Although he doesn’t like serial acquisitors, he likes that this company is very focused on what they are doing. When they make an acquisition, they typically get 50%-51% of the business, so they consolidate it. Their revenue numbers are generally growing much faster than their earnings because they have to take out the minority interests. They are recognizing 100% of the revenues, but effectively are only getting 51% of the earnings. That was one of the thrusts of the Short report. The other was that they were being paid to use an MD to administer their deep sedation (used in colonoscopies), but using specially trained professional nurses instead. A decent company, he is just not sold on it yet.

Showing 1 to 30 of 90 entries

CRH Medical Corp.(CRH-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for CRH Medical Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CRH Medical Corp.(CRH-T) Frequently Asked Questions

What is CRH Medical Corp. stock symbol?

CRH Medical Corp. is a Canadian stock, trading under the symbol CRH-T on the Toronto Stock Exchange (CRH-CT). It is usually referred to as TSX:CRH or CRH-T

Is CRH Medical Corp. a buy or a sell?

In the last year, 1 stock analyst published opinions about CRH-T. 1 analyst recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is WATCH. Read the latest stock experts' ratings for CRH Medical Corp..

Is CRH Medical Corp. a good investment or a top pick?

CRH Medical Corp. was recommended as a Top Pick by Jason Mann on 2020-01-17. Read the latest stock experts ratings for CRH Medical Corp..

Why is CRH Medical Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CRH Medical Corp. worth watching?

1 stock analyst on Stockchase covered CRH Medical Corp. In the last year. It is a trending stock that is worth watching.

What is CRH Medical Corp. stock price?

On 2020-04-03, CRH Medical Corp. (CRH-T) stock closed at a price of $1.94.